PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Mirza, Mansoor R.
TI  - Trial Will Evaluate Niraparib vs Placebo in Platinum-Sensitive Patients with Ovarian Cancer
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 14--14
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/14.1.short
4100  - http://mdc.sagepub.com/content/14/36/14.1.full
AB  - Niraparib is a potent oral PARP1 and PARP2 (poly [ADP-ribose] polymerase) inhibitor with antitumor activity in germline BRCA mutation (gBRCAmut) ovarian cancer and BRCA-negative (non-gBRCAmut) high-grade serous ovarian cancer (HGSOC). This article presents the study design of an ongoing niraparib maintenance study examining platinum-sensitive patients with ovarian cancer and deleterious gBRCAmut or high-grade serous histology non-gBRCAmut [NOVA; NCT01847274].